Related Experiment Videos
Immunosuppressive treatment for multifocal motor neuropathy
T Umapathi1, R A Hughes, E Nobile-Orazio
1Department of Neurology, National Neuroscience Institute, 11 Jalan Tam, Tolk Seng, Singapore, Singapore, 308433. tumapathi@yahoo.com
The Cochrane Database of Systematic Reviews
|June 22, 2002
Summary
No randomized controlled trials exist for immunosuppressive agents in multifocal motor neuropathy (MMN). Current evidence for MMN treatment relies on case series, highlighting a need for rigorous trials.
Area of Science:
- Neurology
- Clinical Trials
- Immunosuppression
Background:
- Multifocal motor neuropathy (MMN) presents with progressive, asymmetrical limb weakness and motor nerve conduction blocks.
- Intravenous immunoglobulin (IVIg) is an established treatment for MMN.
- Immunosuppressive agents are used off-label, necessitating evidence-based evaluation.
Purpose of the Study:
- To systematically review randomized controlled trials (RCTs) evaluating immunosuppressive agents for MMN treatment.
- To assess the efficacy and safety of immunosuppressants in managing MMN.
Main Methods:
- Comprehensive search of multiple databases (Cochrane, MEDLINE, EMBASE, CINAHL, LILACS) for relevant trials.
- Inclusion criteria focused on RCTs and quasi-RCTs; case series were included due to lack of RCTs.
- Data extraction and summarization of treatment outcomes for MMN patients receiving immunosuppressive agents.
Main Results:
- No randomized controlled trials were identified for immunosuppressive agents in MMN.
- Evidence from retrospective and prospective case series was summarized in the review's discussion.
Conclusions:
- There is a lack of high-quality evidence from RCTs to support the use of immunosuppressive agents in MMN.
- Further research through well-designed randomized controlled trials is crucial to establish the role of immunosuppressants in MMN management.